|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Novartis_influenza_vaccine_business
|
|
gptkbp:CEO
|
Marc Lacey (as of 2023)
|
|
gptkbp:focus
|
public health
influenza prevention
|
|
gptkbp:founded
|
2015
|
|
gptkbp:headquartersLocation
|
gptkb:Melbourne,_Australia
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seqirus
|
|
gptkbp:industry
|
pharmaceuticals
vaccines
|
|
gptkbp:manufacturingFacilities
|
gptkb:Liverpool,_UK
gptkb:Holly_Springs,_North_Carolina,_USA
gptkb:Maidenhead,_UK
gptkb:Parkville,_Australia
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Latin_America
gptkb:North_America
gptkb:Asia-Pacific
|
|
gptkbp:notableProduct
|
gptkb:Afluria
gptkb:Flucelvax
gptkb:Fluvirin
gptkb:Fluad
|
|
gptkbp:numberOfEmployees
|
over 3,000
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:parentCompany
|
gptkb:CSL_Limited
|
|
gptkbp:product
|
influenza vaccines
adjuvanted vaccines
cell-based vaccines
egg-based vaccines
pandemic flu vaccines
seasonal flu vaccines
|
|
gptkbp:subsidiary
|
gptkb:CSL_Limited
|
|
gptkbp:website
|
https://www.seqirus.com/
|
|
gptkbp:bfsParent
|
gptkb:CSL_(company)
gptkb:CSL_Limited
gptkb:Commonwealth_Serum_Laboratories
gptkb:Fluad
gptkb:Influenza_Vaccine
gptkb:Novartis_Vaccines_and_Diagnostics
|
|
gptkbp:bfsLayer
|
6
|